{"ModuleTitle": "Company Description", "CompanyName": "BioSpecifics Technologies Corp", "Symbol": "BSTC", "Address": "35 WILBUR ST, LYNBROOK, New York, 11563, United States of America", "Phone": "5165937000", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a biopharmaceutical company involved in the development of an injectable\r\ncollagenase clostridium histolyticum (\"CCH\") for multiple indications. We\r\nmaintain intellectual property with respect to injectable CCH that treats, among\r\nother indications, Dupuytren's contracture (\"DC\"), Peyronie's disease (\"PD\"),\r\nfrozen shoulder syndrome, and uterine fibroids. Injectable CCH currently is\r\napproved and marketed in the U.S. under the trademark XIAFLEX\u00ae for the treatment\r\nof both DC and PD. We generate revenue primarily from our license agreement with\r\nEndo, under which we receive license, sublicense income, royalties, milestones\r\nand mark-up on cost of goods sold payments related to the sale, regulatory\r\nsubmissions and approval of XIAFLEX\u00ae.\r\n \r\nWe have developed injectable CCH for 12 clinical indications to date. We\r\ncurrently are evaluating CCH as a treatment for uterine fibroids.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f16%2f0001140361-20-005848.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Joseph Truitt", "title": "Chief Executive Officer & Director"}, {"name": "Patrick C. Hutchison", "title": "Chief Financial Officer"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}